[1][2][3][4][5] Unity BioTechnologies, a company backed by Jeff Bezos and PayPal co-founder Peter Thiel,[6] was co-founded in March 2009 by Nathaniel David, Jan Van Deursen, Judith Campisi, and Daohong Zhou.

[7] The company was founded under the name Forge, Inc., but changed its name to Unity BioTechnologies in January 2015.

That same year, Nathaniel stepped down as president but remained a member of the board.

[10][11] Unity Biotechnology shares dropped 60% on August 17, 2020, after the company reported disappointing results from a clinical trial involving its then lead drug candidate, UBX0101, in patients with moderate-to-severe painful osteoarthritis.

[12] The company's products in development include UBX1325, which targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 2 clinical trials for diabetic macular edema as of October 2023).